+86 27 8798 8585
| |

Latest News

You are at the location of:Home - Latest News - Industry News

WuXi Biologics Signed Letter of Intent for Long-Term Vaccine Manufacturing Contract

Article source:Station editor Update time:2019-08-09 14:07:54   Browsing times:second

WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has entered into a strategic partnership Letter of Intent (LOI) with a global vaccine leader, pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial product for the global market.

 
Under the LOI, WuXi Vaccines will build an integrated vaccine manufacturing facility including drug substance manufacturing (DS), drug product manufacturing (DP) as well as Quality Control labs (QC). The facility will be dedicated to manufacture 100% of the global market of one of our partner’s vaccine products. The value of the 20-year manufacturing contract is estimated to be more than $3 billion USD.